A spate of news at the start of this year regarding therapies for pulmonary arterial hypertension (PAH) threw fresh light on the disorder - and might put eventual pressure on the Swiss firm Actelion Ltd., which markets the only approved oral therapy: Tracleer (bosentan), the dual endothelin receptor antagonist given market clearance by the FDA in 2001. Read More